Skip to content

Effects of ß-Receptor Blockers on the Prognosis of Immunotherapy in Lung Cancer — A Multi-Center Real-World Cohort Study

Effects of ß-Receptor Blockers on the Prognosis of Immunotherapy in Lung Cancer — A Multi-Center Real-World Cohort Study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400082093
Enrollment
Unknown
Registered
2024-03-20
Start date
2024-03-20
Completion date
Unknown
Last updated
2024-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung cancer

Interventions

Beta blocker group:None
No beta-blocker use group:None

Sponsors

The Second Affiliated Hospital of Kunming Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1)Age = 18 years; 2)Histologically or cytologically confirmed diagnosis of non-small cell lung cancer; 3)At least one measurable lesion according to RECIST 1.1 criteria; 4)Patients determined to be in stage III-IV based on the 8th edition of the AJCC International Lung Cancer TNM staging system; 5)Patients receiving either single-agent immunotherapy or immunotherapy in combination with other treatments.

Exclusion criteria

Exclusion criteria: 1)No clear pathological diagnostic information; 2)Concurrent presence of other tumors; 3)Patients with systemic immune diseases or severe psychiatric disorders; 4)Non-compliance or unwillingness to cooperate.

Design outcomes

Primary

MeasureTime frame
Overall survival;progression-free survival;

Secondary

MeasureTime frame
Objective Response Rate;Disease Control Rate;Duration of Response;clinical benefit rate;Safety and Tolerability;

Countries

Chnia

Contacts

Public ContactHai Bing

The Second Affiliated Hospital of Kunming Medical University

1910645481@qq.com+86 155 5977 2222

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026